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Background. Subtype C is the most prevalent HIV-1 subtype in the world, mainly in countries with the highest HIV prevalence.
However, few studies have evaluated the impact of antiretroviral therapy on this subtype. In southern Brazil, the first
developing country to offer free and universal treatment, subtypes B and C co-circulate with equal prevalence, allowing for an
extensive evaluation of this issue. Methods and Findings. Viral RNA of 160 HIV-1+ patients was extracted, and the protease
and reverse transcriptase genes were sequenced, subtyped and analyzed for ARV mutations. Sequences were grouped by
subtype, and matched to type (PI, NRTI and NNRTI) and time of ARV exposure. Statistical analyses were performed to compare
differences in the frequency of ARV-associated mutations. There were no significant differences in time of treatment between
subtypes B and C groups, although they showed distinct proportions of resistant strains at different intervals for two of three
ARV classes. For PI, 26% of subtype B strains were resistant, compared to only 8% in subtype C (p=0.0288, Fisher’s exact test).
For NRTI, 54% of subtype B strains were resistant versus 23% of subtype C (p=0.0012). Differences were significant from 4
years of exposure, and remained so until the last time point analyzed. The differences observed between both subtypes were
independent of time under rebound viremia in cases of virologic failure and of the number of HAART regimens used by treated
patients. Conclusions. Our results pointed out to a lower rate of accumulation of mutations conferring resistance to ARV in
subtype C than in subtype B. These findings are of crucial importance for current initiatives of ARV therapy roll-out in
developing countries, where subtype is C prevalent.
Citation: Soares EAJM, Santos AFA, Sousa TM, Sprinz E, Martinez AMB, et al (2007) Differential Drug Resistance Acquisition in HIV-1 of Subtypes B and
C. PLoS ONE 2(8): e730. doi:10.1371/journal.pone.0000730
INTRODUCTION
The genetic diversity of human immunodeficiency virus type 1
(HIV-1) allows for its classification in several groups, subtypes, sub-
subtypes and circulating recombinant forms (CRF) [1]. To date, 9
known subtypes and at least 34 CRF are heterogeneously
distributed around the world. While subtype B predominates in
developed countries of Western Europe and U.S., other (non-B)
subtypes or CRF account for the majority of infections in the
developing world [2]. Interestingly, subtype C is responsible for
50% of global HIV infections [2], in countries with the highest
known prevalence (in sub-Saharan Africa), and with large
populations, like India [3,4].
An increasing body of experimental evidence suggested that
different HIV-1 subtypes might exhibit disparate biological
behaviors, and might respond differently to diagnostic, immuno-
logic and therapeutic interventions [5–7]. With respect to HIV
antiretroviral (ARV) treatment, recent studies identified subtype-
specific differences in viral susceptibility to specific drugs [8,9] and
in signature mutations selected by treatment [10–12]. An
important problem, in this scenario, is whether HIV-1 subtypes
may differ in the rate of fixation of mutations conferring drug
resistance in individuals under ARV therapy, a point recently
addressed in a single report [13].
As Brazil exhibits a heterogeneous HIV-1 subtype distribution
[14,15] and a history of universal and free access to ARV therapy
since 1996 [16], it represents an appropriate setting for
retrospectively analyzing the rate of fixation of mutations
conferring drug resistance under specific ARV class exposure, in
different subtypes. In particular, we selected the southernmost
state of Brazil, Rio Grande do Sul, as study site because it is
characterized by an equal distribution of B and C subtypes [17,18]
co-circulating in individuals under similar socio-demographic
conditions. In this report, we found that subtype C is less prone
to fix mutations conferring drug resistance over time when
compared to subtype B counterparts subjected to the same type
and length of ARV drug exposure, in two of three ARV classes.
METHODS
Patients
Regularly followed patients, at two public health system hospitals
in the state of Rio Grande do Sul (Hospital de Clı ´nicas de Porto
Alegre and Hospital Universita ´rio do Rio Grande), participated in
this study. One hundred and sixty patients were initially enrolled.
Eligibility criteria included age above 18 years, current exposure to
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laboratory (CD4
+ T-cell counts and HIV viral load) and treatment
histories. Viral load measurements were conducted with the
Quantiplex HIV-1 RNA 2.0 Assay (Bayer Diagnostics, Tarrytown,
NY, U.S.). Only patients with self-reported adherence to therapy
during all treatment periods were included in analyses. Following
written informed consents (provided by 100% of participants),
plasma specimens were collected and available medical records
were reviewed. All sample collections were conducted from July
2002 to January 2003. This study was approved by the Internal
Review Boards from both Institutions, the Comite ˆd eE ´tica em
Pesquisa do Hospital de Clı ´nicas de Porto Alegre and the Comite ˆd eE ´tica em
Pesquisa na A ´rea de Sau ´de da Fundac ¸a ˜o Universidade Federal do Rio Grande.
HIV-1 molecular characterization and drug
resistance analysis
Viral RNA was extracted from plasma and complementary DNA
synthesis was carried out with random primers as previously
described [19]. Nested polymerase chain-reactions (PCR) were
conducted with specific primers. The entire protease region (PR)
and the first 225 codons of reverse transcriptase (RT) were
amplified, purified with the Qiagen PCR purification kit
(QIAGEN, Valencia, CA) and sequenced in an ABI3100
automated sequencer (Applied Biosystems, Foster City, CA).
Sequences were aligned with SeqMan (DNAStar, Madison, WI)
and manually edited. Edited sequences were subsequently aligned,
with ClustalW [20], to reference sequences representative of all
HIV-1 subtypes available at the Los Alamos database (http://hiv-
web.lanl.gov). Aligned sequences were subjected to phylogenetic
analyses by neighbor-joining and Kimura 2-parameter model of
the MEGA 3.0 package for inference of HIV-1 subtypes [21].
Identification of antiretroviral resistant mutations in PR and RT
genes was carried out following electronic submission to the
Stanford University database (http://hivdb.stanford.edu) [22].
Mutations were recorded according to the International AIDS
Society-USA consensus [23]. Sequence data were submitted to the
GenBank with accession numbers AY275719-AY275807,
AY390079-AY390081, AY390178-AY390190, DQ190959-
DQ191030, DQ343964-DQ344016, and DQ659454-DQ659487.
Data groups and statistical analyses
Demographic and clinical data from patients (age, gender, time of
HIV diagnosis, CD4 T-cell counts, HIV viral load, CDC immune
and clinical staging and treatment status and time of treatment)
were compiled for each subtype (B and C) group and differences
were analyzed with Student’s t-test or Fisher’s exact test.
Sequences were grouped according to their assigned HIV-1
subtype, and further separated according to type of ARV
exposure, nucleoside/nucleotide RT, non-nucleoside RT or
protease inhibitors (NRTI, NNRTI and PI, respectively). Finally,
viral sequences were further grouped according to time of ARV
exposure (in 12-month periods) within each ARV class. Cumu-
lative curves of proportions of mutant viruses within each group
over ARV exposure time were plotted for each subtype (B and C).
Significant differences in the proportion of mutants at each time
point were evaluated by one-tailed Fisher’s exact tests, with
significance level =0.05.
The same analysis was also conducted for patients subjected
exclusively to HAART, to avoid confounding factors of drug
resistance generation by sub-optimal regimens (mono and/or dual
therapy). Additionally, we have compared the proportion of
patients subjected to one or more than one HAART regimen, as
well those that received mono and/or dual therapy prior to
HAART in both subtypes. The average number of mutations per
genome, as well as the proportion of resistant strains in those three
groups was also compared in both subtypes.
Exposure times to individual antiretrovirals were also compiled
for each subtype group for evaluating differences with respect to
specific drugs.
We have also assessed the impact of length of rebound viremia
in treated patients on the acquisition of drug resistance mutations
in both subtypes, by comparing the average time of rebound
viremia in both groups through Student’s t test. The proportion of
resistant viruses among those patients with rebound viremia was
also compared through Fisher’s exact test. Finally, we have also
compared the proportion of patients reaching undetectable viral
load after HAART initiation over time in both subtype groups by
Fisher’s exact test.
RESULTS
Demographic, clinical and molecular profiles
One hundred and sixty patients with known ARV treatment
history were screened for infecting HIV-1 subtype by RT-PCR, by
sequence and phylogenetic analyses of partial pol sequences. Of
these, 136 were infected with either subtype B (n=84) or C
(n=52), which were selected for further analysis. The 24
remaining viral isolates corresponded to subtype F1 (n=11),
subtype D (n=4), and mosaic forms (n=9).
Table 1 summarizes major demographic and clinical parame-
ters for subtype B- and C-infected groups. Of these parameters,
time elapsed from diagnosis to sample collection differed
significantly between both groups, being shorter for subtype C-
infected patients (p=0.013; Student’s t-test). The proportion of
patients in each subtype group classified in CDC clinical stage C
also differed significantly (p=0.05; Fisher’s exact test). Finally,
subtype B-infected patients showed lower CD4 T-cell counts than
subtype C at HAART initiation (p=0.003; Table 1).
All amino acid-deduced pol sequences from treated patients
were analyzed for drug resistance mutations according the IAS-
USA consensus [23]. Most of the RTI- and PI-associated
mutations occurred in both subtype groups, suggesting that
qualitative patterns of drug resistance acquisition were similar.
Some RTI (K65R, L74V) and PI (D30N, M46I/L, I84V)
mutations were only seen in subtype B isolates. Conversely, one
multi-NRTI resistant genotype (A62V, V75I, F116Y and Q151M)
was found among subtype C isolates. Of note, the thymidine
analogue mutations M41L, L210W and the 3TC-associated
mutation M184V/I, as well as the PI mutation L90M, were
significantly more frequent in subtype B isolates (p,0.05, data not
shown). Interestingly, when both patient groups were analyzed
with respect to the number of average mutations per viral genome,
subtype B showed higher numbers for all ARV classes, but only
the difference for protease inhibitors was found significant (0.6
mutations per genome in subtype B versus 0.12 in subtype C;
p,0.01, Student’s t test). This higher accumulation of mutations in
subtype B isolates could not be explained by longer exposure to
ARV therapy because it did not differ from subtype C exposure,
either per class or globally (Table 1). Despite similar times of total
ARV exposure, subtype B might have been exposed to mono and
dual therapy for a longer time because this subtype has been
circulating in Brazil for a longer period than subtype C, at a time
when these regimens were common. This could have selected
mutations faster in subtype B than in C. However, analysis of
previous time of exposure to mono and/or dual therapy in both
groups failed to show significant differences (p=0.9629, Students t
test, data not shown).
Resistance in HIV-1 B and C
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mutations in subtype C isolates compared to subtype B counter-
parts by analyzing mutations in individual ARV classes. For PI,
38% of subtype B isolates presented at least one primary resistance
mutation versus only 8% of subtype C isolates (p=0.0037, Fisher’s
exact test). For NRTI, 56% of subtype B isolates presented
primary resistance versus 23% of subtype C isolates (p=0.0009,
Fisher’s exact test). For NNRTI, no differences in the proportion
of resistant isolates were found between subtypes. In addition to
the ARV class exposure, all patients in both groups had their
complete treatment history assessed and were stratified according
to time of exposure to each ARV class. Patients were cumulatively
pooled in increasing time periods, and the percentage of strains
carrying primary mutations was compared in both subtype groups
(Figure 1 shows these comparisons for each ARV class). For
NRTI-related mutations, subtype C viruses differed significantly
from subtype B from 4 year-exposure, and this difference steadily
increased to 9 year-exposure (Figure 1A). At this point, 54% of
subtype B viruses harbored NRTI-related mutations, whereas less
than half (23%) of subtype C viruses carried these mutations
(p=0.0012, Fisher’s exact test). Protease resistance mutations
occurred significantly at higher levels in subtype B already by 4
years of PI exposure, and also remained significantly higher for up
to 5 years (26% in subtype B versus 8% in subtype C; p=0.0288,
Fisher’s exact test; Figure 1C). In agreement with previous
analyses, NNRTI mutations did not differ significantly in both
subtype groups, at least to 4 years of exposure, the longest
available period (Figure 1B).
Despite that subtype B and C-infected groups did not differ
significantly in time of mono and/or dual therapy previous to
HAART, we further restricted our analyses to patients exclusively
subjected to HAART (Figure 2). The acquisition of resistance
mutations for all ARV classes was identical to those found in
global analyses, indicating that NRTI- and PI-associated muta-
tions accumulated faster for subtype B from year 4 of exposure,
while NNRTI mutations did not differ between both groups.
It was possible that the number of resistance mutations was
associatedwith a differential use ofsequential HAART regimens.To
evaluate this, we have compared patients with one or multiple
HAARTregimensineach subtypegroup with respecttothe average
number of mutations per genome and the proportion of resistant
strains. Despite the fact that similar proportions of patients were
subjected to multiple regimens in both groups (52% of subtype B
versus 42% of subtype C, p=0.11), subtype C had lower proportion
of resistant strains and lower average number of mutations in all
compared treatment groups (Table 2). Even in patients previously
subjected to mono and/or dual therapy, the number of resistant
strains was significantly higher for subtype B (Table 2).
We have also evaluated the role of each individual ARV drug in
the appearance of drug-associated mutations. We calculated the
time of exposure to individual ARV in both subtype groups, taking
into account the global patient dataset, as well as for those only
subjected to HAART (Table 3). Differences in time of exposure to
D4T, 3TC and NFV were seen in the global dataset, but these
differences only remained significant for NFV when analyzing
patients exclusively subjected to HAART. This demonstrated that
in these patients, without significant differences in exposure to
D4T and 3TC, there was a higher accumulation of NRTI-
associated mutations in subtype B (Figure 2A).
Since we observed a longer NFV exposure in subtype B
patients, this ARV might explain the differences observed between
subtype groups in the PI class (Figures 1C and 2C). In fact, half
(10/21) of subtype B-infected patients under NFV presented NFV-
associated mutations, while none of the subtype C isolates (0/8),
under NFV exposure, showed these mutations. For this reason, we
analyzed PI-associated mutations in all patients under NFV as PI
component of their HAART regimen. This showed that subtype B
still accumulated more NFV-associated mutations (primary or
secondary) even when matching time of exposure between subtype
groups (Figure 3). Around 12 months of NFV exposure, some 10%
ofsubtype BstrainsalreadycarriedNFV-associated mutations,while
none of subtype C strains was resistant to NFV. By 24 and 36
months, approximately 30% of subtype B strains already carried
NFV mutations, and differences in the proportion of resistant strains
was already statistically significant (p=0.05; Figure 3). Thus, despite
NFV had been used more extensively in subtype B-infected subjects,
it resistance mutations were positively selected more rapidly when
matching exposure times were analyzed.
We have also investigated the impact of rebound viremia time
on the accumulation of drug resistance. It was plausible that
subtype B patients could have accumulated more mutations
because they have had failed therapy for longer than those infected
with subtype C. We found 24 subtype B- and 17 subtype C-
infected patients with rebound viremia. We have calculated the
average time of rebound viremia for each subtype group, and
found that they do not differ significantly (15.6 months for subtype
B and 19 months for subtype C). Interestingly, we found that the
proportion of those patients carrying drug resistant viruses was
Table 1. Demographic and clinical characteristics of HIV-1-
positive treated patient groups infected with B and C
subtypes.
......................................................................
SUBTYPE B
(n=84)
SUBTYPE C
(n=52) p value
Age (yr/SD) 40.59 (10.86) 40 (12.51) 0.779
Gender (%) 0.131
Male 52 (62) 29 (58)
Female 32 (38) 21 (42)
Average time of diagnosis (yr/SD) 6.42 (3.88) 4.93 (3.02) 0.013*
CDC Clinical Stage (%)
A 23 (27.71) 16 (31.38) 0.139
B 20 (24.10) 17 (33.33) 0.080
C 40 (48.19) 18 (35.29) 0.050
CDC Immune Stage (%)
1 19 (22.62) 11 (21.57) 0.170
2 40 (47.62) 23 (47.06) 0.142
3 25 (29.76) 15 (31.37) 0.154
Average CD4 T-cell counts at HAART
initiation (SD)
135 (108) 254 (154) 0.003
Average CD4 T-cell counts at sample
collection (SD)
334 (212) 334 (195) 0.937
Median log10 viral RNA prior to
HAART initiation
5.2 5.0 0.975
Median log10 viral RNA at sample
collection
2.6 2.0 0.198
Undetectable VL (%) (,80 copies/ml
plasma)
28 (33.7) 22 (44.8) 0.065
Average time of ARV treatment (yr/SD)
NRTI/Total 3.58 (2.18) 2.97 (2.15) 0.116
NNRTI 1.8 (0.98) 1.49 (0.99) 0.187
PI 2.72 (1.83) 2.59 (1.4) 0.687
*Bold p values are significant at the 0.05 level
doi:10.1371/journal.pone.0000730.t001
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Resistance in HIV-1 B and C
PLoS ONE | www.plosone.org 3 August 2007 | Issue 8 | e730Figure 1. HIV-1 subtype B and C viruses with at least one primary resistance mutation. Different treatment exposure periods (in months) were
plotted for each subtype and for each ARV drug class. (A) NRTI, (B) NNRTI, (C) PI. Black asterisks denote significance in the difference of proportions
between subtypes B and C at the 0.05 p value level.
doi:10.1371/journal.pone.0000730.g001
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PLoS ONE | www.plosone.org 4 August 2007 | Issue 8 | e730Figure 2. HIV-1 subtype B and C viruses with primary resistance mutations from individuals undergoing HAART. Different treatment exposure
periods (in months) were plotted for each subtype and for each ARV drug class. (A) NRTI, (B) NNRTI, (C) PI. Black asterisks denote significance in the
difference of proportions between subtypes B and C at the 0.05 p value level.
doi:10.1371/journal.pone.0000730.g002
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PLoS ONE | www.plosone.org 5 August 2007 | Issue 8 | e730significantly higher for subtype B (46%) than for subtype C (18%)
(p=0.048, Fisher’s exact test). We have also checked the
proportion of subtype B- and C-infected patients who had
undetectable VLs over time of therapy, and they did not differ
significantly at any time point, except for the initial suppression
period (until 8 months after HAART initiation). At that time, the
subtype C group had 79% of patients with undetectable VL,
compared to only 52% of the subtype B group (p=0.04, Fisher’s
exact test).
DISCUSSION
The impact of ARV treatment on different HIV-1 subtypes and
CRF is an issue of paramount concern associated to the
introduction of treatment in developing countries. To date,
however, scarce data are available on the impact of ARV in
HIV-1 of non-B subtypes, which paradoxically account for almost
90% of all HIV infections in the world. Southern Brazil represents
an ideal setting for assessing this question because subtypes B (the
most studied) and C (the most prevalent) co-circulate in very
similar frequencies in the same population [15,17,18].
Our group has previously shown that subtype C was introduced
in Brazil later than subtype B [15,18,24], in agreement with our
observation of a shorter time of diagnosis for individuals infected
with subtype C (Table 1). Although the HIV subtype B epidemic is
older, the time of treatment did not differ significantly between B
and C subtypes for all drug classes (Table 1).
When analyzing the rate of accumulation of mutations
conferring drug resistance over time for each major ARV class,
subtype C viruses apparently acquired a lower number of
mutations than subtype B for PI and NRTI, but not for NNRTI.
We ruled out the possibility that previous exposure to mono- or
dual-therapy in subtype B-infected patients (affected by an older
epidemic) might explain these differences. To further investigate
the rate of accumulation of mutations, we stratified subtype groups
by time of therapy at 12 month-intervals. Here again, different
rates between subtypes B and C were observed, for PI and NRTI
mutations, but not for NNRTI. Our data were further confirmed
by similar analyses in patients exclusively subjected to HAART. In
this setting, we definitively excluded the possibility that previous
mono and/or dual therapy accounted for these differences. Of
note, HAART was universally initiated in Brazil with the
introduction of PI in 1996, when the prevalence of subtypes B
and C were already very similar [17,18].
We ruled out that time of exposure to individual ARV drugs,
rather than ARV classes, accounted for different mutation rates
between subtypes B and C. In fact, analysis of the global dataset
showed that D4T, 3TC and NFV were more extensively used in
subtype B patients (Table 3) but the significance of D4T and 3TC
exposure disappeared when analysis was restricted to HAART
patients. This provided strong evidence that differences in NRTI-
related mutations, still present in HAART patients, could not be
attributed to a differential exposure to these drugs. As the use of
NFV was significantly higher in subtype B isolates, we carried out
separate analysis of the time of exposure to this drug matching
exposure time. This analysis showed that subtype B accumulated
NFV-related mutations more rapidly than subtype C.
We have also ruled out the impact of treatment failure time on
the increased drug resistance accumulation in subtype B. Both
subtypes had similar rebound viremia times, but subtype B
retained a higher proportion of resistant strains in failed
individuals. The proportion of virological success (undetectable
viral load, uVL) between subtype groups was similar in all time
periods after HAART initiation, with the exception of the period
spanning 5–8 months of therapy, where a higher proportion of
subtype C had more patients with uVL.
The use of distinct drug regimens (single or multiple HAART,
or previous use of mono and/or dual therapy) did not seem to
influence the higher rates of drug resistance acquisition in subtype
B compared to C. For all types of ARV exposure, the proportion
of resistant strains and the average number of mutations per
genome was lower in subtype C-infected patients, with exception
of patients subjected to mono/dual therapy.
Our observations were unexpected and, to some extent para-
doxical, since all ARV drugs were designed for subtype B, which
Table 2. Comparison of drug resistance mutation acquisition
between subtype B- and C-infected patients under different
therapeutic regimens.
......................................................................
Subtype B Subtype C p-value
One HAART Regimen
Proportion of isolates with at least one
primary resistance mutation
33% (8/24)
a 9.5% (2/21) 0.048
b
Average number of drug resistance
mutations per isolate (SD)
0.5 (0.78) 0.1 (0.3) 0.025
c
Multiple HAART Regimens
Proportion of isolates with at least one
primary resistance mutation
62% (16/26) 20% (03/15) 0.001
Average number of drug resistance
mutations per isolate (SD)
1.8 (3) 0.4 (0.8) 0.027
Previous mono- and/or dual therapy
Proportion of isolates with at least one
primary resistance mutation
56% (15/27) 25% (04/16) 0.039
Average number of drug resistance
mutations per isolate (SD)
2.4 (2.9) 1.1 (2.4) 0.130
Statistically significant p-values (,0.05) are in boldface
aNumber of patients with resistance/total
bFisher’s exact test
cStudent’s t test
doi:10.1371/journal.pone.0000730.t002
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Table 3. Mean time of drug exposure in months for each HIV-
1 subtype-infected group.
......................................................................
Drug
£ Subtype B Subtype C T-test
Total/HAART
# Total/HAART Total/HAART
AZT 27.91/20.98 28.36/19.27 0.9043/0.6327
DDI 24.24/18.58 22.57/16.83 0.7206/0.4501
D4T 27.3/27.6 19/20.1 0.0218*/0.1375
3TC 27.6/24.4 21.4/19.5 0.0304/0.1086
DDC 15.17/17.25 20.75/29.67 0.3494/0.3236
NFV 24.52/23.33 15.61/11.4 0.0092/0.0052
RTV 19.03/15.69 15.32/14.45 0.3227/0.7425
IDV 19.71/14.82 22.4/24.58 0.5349/0.1080
SQV 20.29/16.17 18.44/23.33 0.6961/0.3945
LPV 8.44/5.75 7.38/7.8 0.6887/0.8749
NVP 18.88/20 22.11/23.4 0.6515/0.7590
EFV 18.41/18.45 13.79/12.52 0.0781/0.0662
£The antiretroviral drugs tenofovir and abacavir were not available to patients in
the Public Health System at the time of survey
#Values left to the bar correspond to the total treated patients analyzed in the
study; those at right represent patients which were only subjected to HAART
therapy
*Comparative T-test values in bold are those significant at the 0.05 level
doi:10.1371/journal.pone.0000730.t003
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PLoS ONE | www.plosone.org 6 August 2007 | Issue 8 | e730predominates in developed countries [2]. Furthermore, the presence
of polymorphisms in non-B subtypes, which are considered as
secondary resistance mutations for subtype B [25–27], supports the
proposition that the acquisition of resistance might be enhanced in
non-B subtypes.Holguinetal.[28] showedthatthesepolymorphisms
do not alter susceptibility of non-B subtypes to ARV drugs, while
other authors have reported such differences, pointing out to the
increased susceptibility of some non-B subtypes to some ARV
[29,30]. Genotypic analyses of subtype B- and C-infected patients
undergoing HAART failure in Israel showed several drug resistance
mutations with higher frequency in subtype B viruses [31]. This
study supported the hypothesis that subtype C accumulates
resistance mutations at lower levels than subtype B.
In our study, NNRTI was the only ARV class for which subtype
C did not differ from subtype B with respect to the rate of
acquisition of drug resistance mutations. Evidence that NNRTI-
related mutations appeared at a higher rate in subtype C was
previously reported [13], in agreement with our results.
A straightforward explanation for the findings herein reported
can not be provided in view of the complexity of viral biology. Few
studies are available on differences between group M subtypes in
response to ARV. Recent studies postulated that different subtype-
specific genetic barriers might be operating in the development of
drug resistance [10,32]. Accordingly, some subtypes might
accumulate resistance at different rates than subtype B at definite
amino acid positions in PR and RT. Approximately 30% of
subtype C presented a higher genetic barrier for acquiring
mutation L210W versus 11% among subtype B viruses [32],
although differences at this position, per se, cannot explain the
observed differences for NRTI. It is also conceivable that subtype
C might accumulate fewer mutations because is more susceptible
to the ARV drugs currently in use, as suggested for other non-B
subtypes [29,30]. In fact, Gonzales et al. [7] showed that subtype C
strains from Brazil and Africa were naturally hypersusceptible to
the PI lopinavir. Moreover, subtypes may be operating under
different evolutionary pressures when acquiring specific drug
resistance mutations, as demonstrated for the D30N NFV-
associated mutation in subtype C [11]. We cannot completely
rule out the possibility that we have neglected potentially new,
subtype C-specific drug resistance mutations in our analyses. A
larger study comparing subtype C-infected drug-naı ¨ve and
experienced patients identified three new putative positions (two
in PR and one in RT) [26]. However, the phenotypic and clinical
impact of changes at these codons is yet to be determined. So far,
only mutation 89I/V was found associated with PI treatment for
subtypes C, F and G [19], but this was stated as a secondary
mutation since it does not confer resistance per se. Alternatively, we
may speculate that intrinsic fitness and replicative capacity of
subtypes might account for their ability of accumulating mutations
in the infected host. In this respect, it has been shown that subtype
C is the least fit of all HIV-1 group M subtypes in competition
assays carried out in peripheral blood mononuclear cells,
independently of viral tropism [33,34].
Despite the fact that the lower accumulation of drug resistance
mutations in HIV-1 subtype C has not been elucidated, our
observations are highly relevant for international treatment roll-
out initiatives aiming to extend ARV protocols to developing
countries. These are particularly valid for countries of sub-Saharan
Africa, which concentrate most of the HIV-infected individuals in
the world, mainly by subtype C. Our data may be useful for an
aggressive initiation and expansion of ARV therapy in the
developing world.
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